特集 : 国別レポートが13,000件から検索可能になりました!

特集 : 海外市場の委託調査がセミカスタムベースでお手軽にできます

株式会社グローバルインフォメーション
表紙
市場調査レポート
商品コード
949233

心臓マーカー分析装置の世界市場:製品分析、企業の事業・マーケティング戦略、主要取引

Global Cardiac Marker Analyzer Market, Product Analysis, Companies Business & Marketing Strategy, Major Deals

出版日: | 発行: iGate Research Pvt Ltd | ページ情報: 英文 118 Pages | 納期: 即納可能 即納可能とは

価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=105.84円
心臓マーカー分析装置の世界市場:製品分析、企業の事業・マーケティング戦略、主要取引
出版日: 2020年07月14日
発行: iGate Research Pvt Ltd
ページ情報: 英文 118 Pages
納期: 即納可能 即納可能とは
  • 全表示
  • 概要
  • 図表
  • 目次
概要

世界の心臓マーカー分析装置市場は、2026年には45億米ドルに達すると予測されています。診断のパラダイムである心臓マーカー分析装置は高感度で信頼性の高い情報を数分で提供することが可能であり、ポイントオブケアテストと実験室どちらの使用にも適してます。心血管疾患の発生率の増加、老年人口の急増、心臓バイオマーカー研究のための官民組織からの資金調達の増加、新しい心臓バイオマーカー同定のための進行中の臨床試験などの要因が同市場の成長を牽引しています。ただし、サンプルの収集と保管に関連する技術的な問題、規制システムと償還システムに関連する問題などの要因は、同市場の成長を妨げている主な要因の一部です。

当レポートは、世界の心臓マーカー分析装置市場について調査しており、市場の動向や予測、COVID-19の影響、競合情勢、主要企業の製品・動向・戦略分析などの情報を提供しています。

目次

第1章 エグゼクティブサマリー

第2章 COVID-19の影響

第3章 市場と予測(2011-2026)

第4章 心臓マーカー企業:比較検査分析

第5章 競合製品分析

第6章 Alere(現在のAbbott)

  • Alere Triage
    • Alere Cardiology純売上高(2010-2016)

第7章 Quidel Corporation

  • Quidel Triage system
    • Quidel Cardiac Immunoassay純売上高(2017-2026)

第8章 Abbott Point of Care

  • The i-STAT System
  • Abbott Laboratories Point of Care Diagnostics 売上高(2011-2026)

第9章 Roche

  • Cobas h 232 POC System

第10章 Beckman Coulter

  • Access 2 Immunoassay System

第11章 Siemens Healthineers

  • Stratus CS Analyzer
  • Siemens Healthineers:ヘルスケアのデジタル化を推進する世界デジタルエコシステムの確立

第12章 Response Biomedical

  • 心血管検査
    • 急性心筋梗塞(心臓発作)検査
    • うっ血性心不全(CHF)検査
    • 血栓症の検査
  • RAMPプラットフォーム
    • RAMP 200
    • RAMP Reader
  • Response心血管検査
    • RAMP® TROPONIN I
    • RAMP® NT-proBNP
    • RAMP® MYOGLOBIN
    • RAMP® CK-MB
    • RAMP® D-DIMER
    • Response心血管検査の純売上高(2010-2026)

第13章 Boditech

  • i-chroma DUO Analyzer

第14章 Lifesign

  • DXpress Reader Analyzer

第15章 LSI Medience Corporation

  • PATHFAST Analyzer

第16章 CardioGenics Holdings Inc.

  • QL Care Analyzer

第17章 Trinity Biotech

  • Meritas POC Analyzer
  • Trinity Biotech Point of Care Diagnostics売上高(2010-2019)

第18章 合併、買収、およびライセンス契約

  • Alere Inc
  • CardioGenics
  • Response Biomedical
  • Abbott Laboratories
  • Siemens Healthineers
  • LSI Medience Corporation
  • Trinity Biotech
  • Quidel

第19章 新しいマーカー

第20章 Response Biomedical:ビジネスとマーケティング戦略

  • 中国の新しい代理店
  • 日本のAlere Medicalとの戦略的提携
  • Response Biomedical:カナダ保健省の承認とCEマークの取得
  • 効率の向上とコストの削減に重点を置く

第21章 Roche:ビジネスとマーケティング戦略

  • 完全に接続されたコアラボの実装
  • Roche:精度を向上させたポイントオブケア(POC)トロポニンテストを発表
  • Roche:タブレット向けの新しいモバイルアプリケーションを発表

第22章 Boditech Med Inc:ビジネスとマーケティング戦略

  • Boditech MedによるImmunosticsの買収
  • 多様化するマーケティングチャネル

第23章 Siemens Healthineers:ビジネスとマーケティング戦略

  • Siemens Healthineers:Teamplay Digital Health Platformを発表
  • Siemens Healthineers:新しい戦略的関係の発表
  • SiemensとImricorの戦略的提携
  • Siemens Healthineers:高感度トロポニンI IVDアッセイの提供
  • Siemens Healthineers:ヘルスケアのデジタル化を推進する世界のデジタルエコシステムを確立
  • Siemens HealthineersとEbitの提携
図表

List of Figures:

  • Figure 3-1: Global - Cardiac Marker Analyzer Market (Million US$), 2011 - 2019
  • Figure 3-2: Global - Forecast for Cardiac Marker Analyzer Market (Million US$), 2020 - 2026
  • Figure 6-1: Global - Alere Cardiology Net Sales (Million US$), 2010 - 2016
  • Figure 7-1: Quidel - Cardiac Immunoassay Revenue (Million US$), 2017 - 2019
  • Figure 7-2: Quidel - Forecast for Cardiac Immunoassay Revenue (Million US$), 2020 - 2026
  • Figure 8-1: Global - Abbott Laboratories Point of Care Diagnostics Sales (Million US$), 2011 - 2019
  • Figure 8-2: Global - Forecast for Abbott Laboratories Point of Care Diagnostics Sales (Million US$), 2020 - 2026
  • Figure 12-1: Global - Response Biomedical Cardiovascular Product Sales (Million US$), 2010 - 2019
  • Figure 12-2: Global - Forecast for Response Biomedical Cardiovascular Product Sales (Million US$), 2020 - 2026
  • Figure 17-1: Global - Trinity Biotech Point of Care Diagnostics Sales (Million US$), 2010 - 2019

List of Tables:

  • Table 4-1: Cardiac Marker Companies - Comparative Tests Analysis
  • Table 4-2: Cardiac Marker Companies - Comparative Tests Analysis
  • Table 4-3: Cardiac Marker Companies - Comparative Tests Analysis
  • Table 5-1: Cardiac Marker Analyzer - Competitive Product Analysis
  • Table 5-2: Cardiac Marker Analyzer - Competitive Product Analysis
  • Table 6-1: Alere - Triage Product Analytes
  • Table 15-1: PATHFAST - Technical Specifications
  • Table 18-1: Alere - Merger & Acquisition, 2007 - 2017
  • Table 18-2: Alere - Distribution/Partnership Agreement, 2008, 2016
  • Table 18-3: CardioGenics - Mergers & Acquisition, 2015
  • Table 18-4: CardioGenics - Licensing Agreement, 2012
  • Table 18-5: Response Biomedical - Distribution Agreement, 2011 - 2015
  • Table 18-6: Response Biomedical - Collaboration Deal, 2004 - 2015
  • Table 18-7: Abbott Laboratories - Merger & Acquisition, 2003, 2017, 2019
  • Table 18-8: Siemens Healthineers - Merger & Acquisition, 2017
  • Table 18-9: Siemens Healthineers - Strategic Partnership, 2017
  • Table 18-10: LSI Medience Corporation - Strategic Alliance, 2014
  • Table 18-11: Trinity Biotech - Merger & Acquisition, 2012
  • Table 18-12: Quidel Corporation - Merger & Acquisition, 2017
目次

The global Cardiac Marker Analyzer market is predicted to reach US$ 4.5 Billion by 2026. Cardiac biomarkers are used as risk stratification for various cardiovascular diseases (CVDs), which include myocardial infraction, congestive heart failure, acute coronary syndrome (ACS) among others. The cardiac biomarkers that are widely used as an integrated diagnostic approach for CVDs include CK-MB, troponin I and T, myoglobin, BNPs, IMA and few others. The prevention of cardiac diseases by monitoring the heart conditions via cardiac biomarker testing is the profound approach for obtaining rapid results for immediate diagnosing and treatment.

Cardiac Marker analyzer represents a paradigm in diagnostics that provides high sensitivity and reliable information in minutes. It is ideally suited to both point of care testing and laboratory use. The factors such as increasing incidences of cardiovascular diseases, rapidly increasing geriatric population, growing funding from public-private organizations for research on cardiac biomarkers, and ongoing clinical trials for the identification of novel cardiac biomarkers are driving the growth of the market. However, factors such as technical problems related to sample collection and storage and issues related to regulatory and reimbursement systems are some of the key factors hampering the growth of this market.

Key Highlights of the Report

  • In October 2017, Abbott completed its acquisition of Alere, concluding a deal first announced in February 2016.
  • Abbott Point of Care Diagnostics sales is driven by continued adoption of Abbott's i-STAT handheld system.
  • Quidel's cardiac immunoassay revenue was valued around US$ 266.5 Million in 2019.
  • Cobas H232 POC system permits rapid and easy determination of cardiac blood markers such as Troponin T, NT-proBNP, D-dimer, CK-MB and myoglobin.
  • A major focus of Response Biomedical development programs in cardiovascular testing has been clinical tests for the quantification of cardiovascular markers.
  • Response Biomedical sells tests that detect three of the primary markers for the detection of an acute myocardial infarction: Troponin I, Myoglobin and CK-MB.
  • In March 2020, Siemens Healthineers announced market introduction of the teamplay digital health platform.
  • CardioGenics is the only company to successfully deploy CL in a compact, fully automated POC platform.
  • Abbott acquired St. Jude Medical, to reap benefits of the latter's strong global position in thriving cardiac areas such as heart failure, atrial fibrillation, structural heart, and chronic pain complement.
  • Trinity Biotech Point-of-Care revenues declined in 2019 by around 23.2% from the previous year figure.
  • In October 2017, Boditech Med has made an agreement with their Chinese distributor, Joinstar, to supply their products for US$ 48 Million over three years.

iGATE RESEARCH report titled "Global Cardiac Marker Analyzer Market, Product Analysis, Companies Business & Marketing Strategy, Major Deals" provides a comprehensive assessment of the cardiac marker analyzer segments, comparative tests analysis, competitive product analysis, product features & benefits, merger & acquisitions, strategic alliances and Companies Business and Market Strategies.

This 118 Page report with 10 Figures and 19 Tables has been studied from 7 View Points:

  • 1. Cardiac Marker Analyzer Market & Forecast (2011 - 2026)
  • 2. Cardiac Marker Companies - Comparative Tests Analysis
  • 3. Cardiac Marker Analyzer - Competitive Product Analysis
  • 4. Cardiac Marker Analyzer - Specifications, Product Features & Benefits Analysis
  • 5. Cardiac Marker Analyzer - Mergers, Acquisitions, Distribution, Partnership and Licensing Agreements
  • 6. Emerging Markers Analysis
  • 7. Companies Business & Marketing Strategy

The Cardiac Marker Analyzer Covered in the report are as follows:

  • 1. Triage MeterPro Analyzer
  • 2. The i-STAT System
  • 3. Cobas h 232 POC System
  • 4. Access 2 Immunoassay System
  • 5. Stratus CS Analyzer
  • 6. RAMP 200
  • 7. RAMP Reader
  • 8. i-chroma DUO Analyzer
  • 9. Dxpress Reader Analyzer
  • 10. PATHFAST Analyzer
  • 11. QL Care Analyzer
  • 12. Meritas POC Analyzer

Cardiac Marker Analyzer - Key Company Analysis

  • 1. Alere (Now Abbott)
  • 2. Abbott Point of Care
  • 3. Quidel Corporation
  • 4. Roche
  • 5. Beckman Coulter
  • 6. Siemens Healthineers
  • 7. Response Biomedical
  • 8. Boditech
  • 9. Lifesign
  • 10. LSI Medience Corporation
  • 11. CardioGenics Holdings Inc.
  • 12. Trinity Biotech

Data Sources

iGATE RESEARCH employs rigorous primary and secondary research techniques in developing distinctive data sets and research material for business reports. This report is built by using data and information sourced from Proprietary Information Database, Primary and Secondary Research Methodologies, and In house analysis by iGATE Research dedicated team of qualified professionals with deep industry experience and expertise.

Research Methodologies

  • Primary Research Methodologies: Questionnaires, Surveys, Interviews with Individuals, Small Groups, Telephonic Interview, etc.
  • Secondary Research Methodologies: Printable and Non-printable sources, Newspaper, Magazine and Journal Content, Government and NGO Statistics, white Papers, Information on the Web, Information from Agencies Such as Industry Bodies, Companies Annual Report, Government Agencies, Libraries and Local Councils and a large number of Paid Databases.

Table of Contents

1. Executive Summary

2. Impact of COVID-19 on Global Cardiac Marker Analyzer Market

3. Global Cardiac Marker Analyzer Market & Forecast (2011-2026)

4. Cardiac Marker Companies-Comparative Tests Analysis

5. Cardiac Marker Analyzer-Competitive Product Analysis

6. Alere (Now Abbott)

  • 6.1. Alere Triage
    • 6.1.1. Alere Cardiology Net Sales (2010-2016)

7. Quidel Corporation

  • 7.1. Quidel Triage system
    • 7.1.1. Quidel Cardiac Immunoassay Net Sales (2017-2026)

8. Abbott Point of Care

  • 8.1. The i-STAT System
  • 8.2. Abbott Laboratories Point of Care Diagnostics Sales (2011-2026)

9. Roche

  • 9.1. Cobas h 232 POC System

10. Beckman Coulter

  • 10.1. Access 2 Immunoassay System

11. Siemens Healthineers

  • 11.1. Stratus CS Analyzer
  • 11.2. Siemens Healthineers establishes global Digital Ecosystem to drive Digitalization of Healthcare

12. Response Biomedical

  • 12.1. Cardiovascular Testing
    • 12.1.1. Acute Myocardial Infarction (Heart Attack) Testing
    • 12.1.2. Congestive Heart Failure ("CHF") Testing
    • 12.1.3. Thrombotic Disease Testing
  • 12.2. RAMP Platform
    • 12.2.1. RAMP 200
    • 12.2.2. RAMP Reader
  • 12.3. Response Cardiovascular Testing
    • 12.3.1. RAMP® TROPONIN I
    • 12.3.2. RAMP® NT-proBNP
    • 12.3.3. RAMP® MYOGLOBIN
    • 12.3.4. RAMP® CK-MB
    • 12.3.5. RAMP® D-DIMER
    • 12.3.6. Response Biomedical Cardiovascular Net Sales (2010-2026)

13. Boditech

  • 13.1. i-chroma DUO Analyzer

14. Lifesign

  • 14.1. DXpress Reader Analyzer

15. LSI Medience Corporation

  • 15.1. PATHFAST Analyzer

16. CardioGenics Holdings Inc.

  • 16.1. QL Care Analyzer

17. Trinity Biotech

  • 17.1. Meritas POC Analyzer
  • 17.2. Trinity Biotech Point of Care Diagnostics Sales (2010-2019)

18. Mergers, Acquisitions and Licensing Agreements

  • 18.1. Alere Inc
  • 18.2. CardioGenics
  • 18.3. Response Biomedical
  • 18.4. Abbott Laboratories
  • 18.5. Siemens Healthineers
  • 18.6. LSI Medience Corporation
  • 18.7. Trinity Biotech
  • 18.8. Quidel

19. Emerging Markers

20. Response Biomedical-Business & Marketing Strategy

  • 20.1. New Distributors in China
  • 20.2. Strategic Alliances with Alere Medical in Japan
  • 20.3. Response Biomedical Receives Health Canada Approval and CE Mark
  • 20.4. Focus on Improving Efficiencies and Reducing Costs

21. Roche-Business & Marketing Strategy

  • 21.1. Implementing the Fully Connected Core Laboratory
  • 21.2. Roche Launches Point-Of-Care (POC) Troponin Test with Improved Accuracy
  • 21.3. Roche Launches New Mobile Application for Tablets

22. Boditech Med Inc-Business and Marketing Strategy

  • 22.1. Boditech Med Acquires Immunostics
  • 22.2. Diversifying Marketing Channel

23. Siemens Healthineers-Business and Marketing Strategy

  • 23.1. Siemens Healthineers Introduces Teamplay Digital Health Platform
  • 23.2. Siemens Healthineers Announces New Strategic Relationship
  • 23.3. Strategic Partnership between Siemens and Imricor
  • 23.4. Siemens Healthineers Offers True High-Sensitivity Troponin I IVD Assay
  • 23.5. Siemens Healthineers Establishes Global Digital Ecosystem to Drive Digitalization of Healthcare
  • 23.6. Partnership between Siemens Healthineers and Ebit
株式会社グローバルインフォメーション
© Copyright 1996-2020, Global Information, Inc. All rights reserved.